Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1Approved for marketing 1

Sponsor Class

OTHER 2

Study Type

Interventional 1Expanded_access 1

Sponsor

Cancer Type

Sarcoma 2Other hematologic neoplasm 2Lymphoid 2

Conditions

Lymphoma 4Renal Insufficiency 2Osteosarcoma 2Lymphoma, Large B-Cell, Diffuse 2Leukemia 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Neurotoxicity Syndromes 1Neoplasms 1Mucositis 1Drug-Related Side Effects and Adverse Reactions 1

Interventions

glucarpidase 2safinamide 1sacubitril and valsartan sodium hydrate drug combination 1ripretinib 1mirabegron 1gamma-Glutamyl Hydrolase 1Sitagliptin Phosphate 1Rituximab 1Methotrexate 1Leucovorin 1Lenalidomide 1Eplerenone 1Duration of Therapy 1Cyclophosphamide 1Cilengitide 1Carboxypeptidases 1Bendamustine Hydrochloride 1Azacitidine 13-(5-amino-2-methyl-4-oxoquinazolin-3(4H)-yl)piperidine-2,6-dione 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Renal Insufficiency × glucarpidase × Lymphoid × Clear all
NCT00634504 2022-06-06

LVPK

BTG International Inc.

Phase 1 Completed
20 enrolled 9 charts
LymphoidOther hematologic neoplasmSarcoma

Leukemia, Lymphoma, Osteosarcoma, Renal Insufficiency

NCT00481559 2014-01-17

Treatment Protocol of Voraxaze for Patients Experiencing or at Risk of Methotrexate Toxicity

BTG International Inc.

Approved for marketing
LymphoidOther hematologic neoplasmSarcoma

Leukemia, Lymphoma, Neoplasms, Osteosarcoma, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡